Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma cells
收藏官方服务：
资源简介：
Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma cells
应用场景：
创建时间：
2011-06-04
相关数据集
Wogonin-derived chemotype enables discovery of novel GLS1 inhibitors with potent antitumor activity
This study evaluates LX-191, a wogonin-derived glutaminase-1 (GLS1) inhibitor featuring a non-BPTES chemotype, designed to overcome the limitations of existing GLS1-targeted therapies. Following targ
NIAID Data Ecosystem110
RNF25-Mediated NF-κB Activation Drives Anti-Apoptosis and Therapy Resistance in Cancer
RNF25-Mediated NF-κB Activation Drives Anti-Apoptosis and Therapy Resistance in Cancer
integrated proteome resources90
Identifying States of Collateral Sensitivity During the Evolution of Therapy Resistance in Ewing’s Sarcoma Poster for 2019 AACR
Two Ewing's sarcoma cell lines were evolved in the standard chemotherapy treatment given to patients. After each dose of chemotherapy treatment, drug sensitivity profiles were captured on each cell li
NIAID Data Ecosystem50
Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence. Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence
Chronic IL-1 treatment selects for cells that are less sensitive to cytotoxicity associated with serum starvation, loss of AR expression, and inflammatory cytokine signaling. Overall design: LNCaP cel
NIAID Data Ecosystem100
Network-based elucidation of colon cancer drug resistance by phosphoproteomic time-series analysis
Aberrant signaling pathway activity is a hallmark of tumorigenesis and progression, which has guided targeted inhibitor design for over 30 years. Yet, adaptive resistance mechanisms, induced by rapid,
NIAID Data Ecosystem70
